M&A Deal Summary |
|
|---|---|
| Date | 2017-03-28 |
| Target | Astellas Pharma - 16 Long-Listed Products |
| Sector | Medical Products |
| Buyer(s) | LTL Pharma |
| Sellers(s) | Astellas Pharma |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
LTL Pharma is a pharmaceutical platform specializing in the acquisition and stable supply of off-patent, long listed products. LTL Pharma was founded in 2016 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 2 |
| Country (Japan) | 1 of 1 |
| Year (2017) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-08-04 |
Sanofi SA - Dellegra
Paris, France Sanofi SA - Dellegra is a combination tablet that is an oral drug combining “Allegra” (Generic Name: Fexofenadine), which is a 2nd generation antihistamine, and Pseudoephedrine, which is an alpha-adrenergic agonist along with the effect of shrinking blood vessels. One tablet of Dellegra® helps patients with allergic rhinitis and moderate or higher nasal congestion to ease three major symptoms of allergic rhinitis (sneeze, runny nose, and stuffy nose) altogether. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1923 |
| Sector | Life Science |
| Employees | 14,754 |
| Revenue | 1.60T JPY (2024) |
Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 2 of 2 |
| Country (Japan) | 1 of 1 |
| Year (2017) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-28 |
Ganymed Pharmaceuticals AG
Mainz, Germany Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. |
Buy | €422M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-03 |
Ogeda SA
Gosselies, Belgium Ogeda SA is a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. |
Buy | €500M |
